UA101681C2 - Изолированное антитело, которое специфически связывается с рецептором фактора роста фибробластов -3 и фармацевтическая композиция, которая содержит указанное антитело - Google Patents

Изолированное антитело, которое специфически связывается с рецептором фактора роста фибробластов -3 и фармацевтическая композиция, которая содержит указанное антитело

Info

Publication number
UA101681C2
UA101681C2 UAA201104814A UAA201104814A UA101681C2 UA 101681 C2 UA101681 C2 UA 101681C2 UA A201104814 A UAA201104814 A UA A201104814A UA A201104814 A UAA201104814 A UA A201104814A UA 101681 C2 UA101681 C2 UA 101681C2
Authority
UA
Ukraine
Prior art keywords
antibody
pharmaceutical composition
specifically binds
growth factor
factor receptor
Prior art date
Application number
UAA201104814A
Other languages
English (en)
Ukrainian (uk)
Inventor
Хайчжун Сун
Лин Лю
Original Assignee
Имклоун Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имклоун Ллк filed Critical Имклоун Ллк
Publication of UA101681C2 publication Critical patent/UA101681C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к изолированному антителу или его фрагменту, который специфично связывается с человеческим FGFR-3(IIIb) и FGFR-3(IIIc). Также изобретение относится к фармацевтической композиции, которая содержит упомянутое антитело для лечения рака.
UAA201104814A 2008-10-20 2009-10-15 Изолированное антитело, которое специфически связывается с рецептором фактора роста фибробластов -3 и фармацевтическая композиция, которая содержит указанное антитело UA101681C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19685508P 2008-10-20 2008-10-20
PCT/US2009/060840 WO2010048026A2 (en) 2008-10-20 2009-10-15 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Publications (1)

Publication Number Publication Date
UA101681C2 true UA101681C2 (ru) 2013-04-25

Family

ID=42062445

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201104814A UA101681C2 (ru) 2008-10-20 2009-10-15 Изолированное антитело, которое специфически связывается с рецептором фактора роста фибробластов -3 и фармацевтическая композиция, которая содержит указанное антитело

Country Status (17)

Country Link
US (3) US8043618B2 (ru)
EP (1) EP2342232A2 (ru)
JP (1) JP5577345B2 (ru)
KR (1) KR101370798B1 (ru)
CN (2) CN102186884B (ru)
AR (1) AR073770A1 (ru)
AU (1) AU2009307841B2 (ru)
BR (1) BRPI0919832A8 (ru)
CA (1) CA2741127C (ru)
EA (1) EA021584B1 (ru)
IL (1) IL211807A0 (ru)
MX (1) MX2011004317A (ru)
NZ (1) NZ592369A (ru)
TW (1) TWI381848B (ru)
UA (1) UA101681C2 (ru)
WO (1) WO2010048026A2 (ru)
ZA (1) ZA201101938B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
SI3702371T1 (sl) 2009-03-25 2023-01-31 Genentech, Inc. Protitelesa proti FGFR3 in postopki za uporabo le-teh
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
WO2014111744A1 (en) 2013-01-16 2014-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
CN105246511A (zh) 2013-03-06 2016-01-13 豪夫迈·罗氏有限公司 治疗和预防癌症药物抗性的方法
TWI541022B (zh) * 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
WO2015148708A1 (en) 2014-03-25 2015-10-01 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
WO2015187521A2 (en) * 2014-06-03 2015-12-10 Merck Sharp & Dohme Corp. Anti-blys antibodies
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
KR20170048560A (ko) * 2014-09-05 2017-05-08 하이퍼파인 리서치, 인크. 낮은 필드 자기 공명 이미징 방법들 및 장치
BR112017017700A2 (pt) * 2015-02-19 2018-07-31 Bioclin Therapeutics Inc métodos, composições e kits para tratamento do câncer
US20180237424A1 (en) 2015-03-03 2018-08-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Fgfr3 antagonists
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
JP2018536682A (ja) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
WO2018129451A2 (en) * 2017-01-09 2018-07-12 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
US11505611B2 (en) 2020-08-21 2022-11-22 Genzyme Corporation FGFR3 antibodies and methods of use
CN114015770B (zh) * 2021-12-30 2022-04-26 佛山市第三人民医院(佛山市精神卫生中心) 精神分裂全外周血rna标志物fgfr3及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
DE60233509D1 (de) 2001-06-20 2009-10-08 Fibron Ltd Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
US20070248605A1 (en) 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
CA2654502C (en) * 2006-06-06 2015-07-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
MY170607A (en) * 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
DK2185719T3 (en) * 2007-08-02 2014-02-17 Novimmune Sa ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
TWI564021B (zh) * 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物

Also Published As

Publication number Publication date
JP5577345B2 (ja) 2014-08-20
US8182815B2 (en) 2012-05-22
US20100098696A1 (en) 2010-04-22
BRPI0919832A8 (pt) 2019-01-08
JP2012505912A (ja) 2012-03-08
US8404240B2 (en) 2013-03-26
EP2342232A2 (en) 2011-07-13
IL211807A0 (en) 2011-06-30
KR101370798B1 (ko) 2014-03-14
AU2009307841B2 (en) 2013-09-12
AR073770A1 (es) 2010-12-01
TW201026325A (en) 2010-07-16
ZA201101938B (en) 2012-08-29
EA201170590A1 (ru) 2011-10-31
WO2010048026A2 (en) 2010-04-29
MX2011004317A (es) 2011-06-24
US20120219563A1 (en) 2012-08-30
NZ592369A (en) 2013-02-22
WO2010048026A3 (en) 2010-07-15
TWI381848B (zh) 2013-01-11
AU2009307841A1 (en) 2010-04-29
BRPI0919832A2 (pt) 2015-12-15
US20120009200A1 (en) 2012-01-12
CA2741127C (en) 2015-06-02
CN102186884A (zh) 2011-09-14
US8043618B2 (en) 2011-10-25
CA2741127A1 (en) 2010-04-29
CN102186884B (zh) 2014-08-13
CN103524620A (zh) 2014-01-22
KR20110056554A (ko) 2011-05-30
EA021584B1 (ru) 2015-07-30

Similar Documents

Publication Publication Date Title
UA101681C2 (ru) Изолированное антитело, которое специфически связывается с рецептором фактора роста фибробластов -3 и фармацевтическая композиция, которая содержит указанное антитело
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
UA104585C2 (ru) Композиция, содержащая антитело, которое связывается с доменом ii her2, и его кислые варианты
PH12017501461A1 (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
UA99633C2 (ru) Антитело, специфически связывающееся с человеческим белком ron
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
HK1243943A1 (zh) 使用抗IL-1α抗體治療癌症
JO3330B1 (ar) الأجسام المضادة cgrp
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
JO3096B1 (ar) الأجسام المضادة لمستقبل ii مضاد tgfb
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
SG170809A1 (en) Diarylthiohydantoin compounds
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
JO2576B1 (en) Antibodies
IL210221A (en) Antibodies that bind notch 2 and / or notch 3 from a human source and preparations that include the above for the treatment of cancer
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
IL214845A (en) Transgenic human antibody 1– dkk or part of its antigen-binding and pharmacological preparations containing it for use in cancer treatment
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
UA106529C2 (ru) Гуманизированное антитело к cxcr4 для лечения рака
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
IL198202A0 (en) Peptide-cytotoxic conjugates